[go: up one dir, main page]

MXPA05009611A - Piperidinas sustituidas como nuevos inhibidores de mdm2-p53. - Google Patents

Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.

Info

Publication number
MXPA05009611A
MXPA05009611A MXPA05009611A MXPA05009611A MXPA05009611A MX PA05009611 A MXPA05009611 A MX PA05009611A MX PA05009611 A MXPA05009611 A MX PA05009611A MX PA05009611 A MXPA05009611 A MX PA05009611A MX PA05009611 A MXPA05009611 A MX PA05009611A
Authority
MX
Mexico
Prior art keywords
inhibitors
formula
substituted piperidines
iii
pharmaceutically acceptable
Prior art date
Application number
MXPA05009611A
Other languages
English (en)
Inventor
Kim Kyungjin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05009611A publication Critical patent/MXPA05009611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion proporciona compuestos que tienen la formula (II) o la formula (III) y las sales farmaceuticamente aceptables de los mismos, en donde X, n y R1-R12 son como se definen en la presente. La invencion tambien proporciona una composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de un compuesto representado por la formula (II) o (III) y un vehiculo o excipiente farmaceuticamente aceptable. Los compuestos son utiles para el tratamiento de cancer.
MXPA05009611A 2003-03-13 2004-03-08 Piperidinas sustituidas como nuevos inhibidores de mdm2-p53. MXPA05009611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45438703P 2003-03-13 2003-03-13
PCT/EP2004/002339 WO2004080460A1 (en) 2003-03-13 2004-03-08 SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS

Publications (1)

Publication Number Publication Date
MXPA05009611A true MXPA05009611A (es) 2005-10-18

Family

ID=32990900

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009611A MXPA05009611A (es) 2003-03-13 2004-03-08 Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.

Country Status (11)

Country Link
US (2) US6916833B2 (es)
EP (1) EP1605941A1 (es)
JP (1) JP4468897B2 (es)
KR (1) KR100755767B1 (es)
CN (1) CN100372837C (es)
AU (1) AU2004218842B2 (es)
BR (1) BRPI0408338A (es)
CA (1) CA2516145A1 (es)
MX (1) MXPA05009611A (es)
RU (1) RU2333201C2 (es)
WO (1) WO2004080460A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000132A (es) * 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
JPWO2008072655A1 (ja) 2006-12-14 2010-04-02 第一三共株式会社 イミダゾチアゾール誘導体
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
KR20120013403A (ko) * 2009-04-22 2012-02-14 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011060049A2 (en) 2009-11-12 2011-05-19 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
EP2638046A4 (en) 2010-11-12 2014-06-25 Univ Michigan SPIRO-oxindole-MDM2 ANTAGONISTS
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
KR101851270B1 (ko) * 2015-07-10 2018-04-25 고려대학교 산학협력단 자연 살해세포의 대량증식 방법 및 배양용 조성물
CN109311900A (zh) 2016-04-06 2019-02-05 密执安大学评议会 用于配体依赖性靶蛋白质降解的单官能中间体
KR102387316B1 (ko) 2016-04-06 2022-04-15 더 리젠츠 오브 더 유니버시티 오브 미시간 Mdm2 단백질 분해제
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN108088727B (zh) 2016-11-21 2020-07-07 中国科学院大连化学物理研究所 一种离体体液中蛋白质的预处理方法
EP3863720A1 (en) 2018-10-08 2021-08-18 The Regents Of The University Of Michigan Small molecule mdm2 protein degraders
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286095A (en) * 1976-08-05 1981-08-25 Canada Packers Inc. 4-Arylpiperidine derivatives
SE7708555L (sv) * 1976-08-05 1978-02-06 Delmar Chem 4-arylpiperidinderivat och forfarande for framstellning derav
SE9400447D0 (sv) * 1994-02-11 1994-02-11 Astra Ab New compounds
US6274735B1 (en) * 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
GB9912961D0 (en) * 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors

Also Published As

Publication number Publication date
CN100372837C (zh) 2008-03-05
US6916833B2 (en) 2005-07-12
CA2516145A1 (en) 2004-09-23
RU2005131501A (ru) 2006-05-27
AU2004218842B2 (en) 2009-11-12
US20040180929A1 (en) 2004-09-16
KR20050106505A (ko) 2005-11-09
US20050171157A1 (en) 2005-08-04
RU2333201C2 (ru) 2008-09-10
JP4468897B2 (ja) 2010-05-26
AU2004218842A1 (en) 2004-09-23
EP1605941A1 (en) 2005-12-21
BRPI0408338A (pt) 2006-03-21
US7060713B2 (en) 2006-06-13
WO2004080460A1 (en) 2004-09-23
KR100755767B1 (ko) 2007-09-10
JP2006519767A (ja) 2006-08-31
CN1758909A (zh) 2006-04-12

Similar Documents

Publication Publication Date Title
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20074021B (en) Hetero biaryl derivatives as matrix metalloproteinase inhibitors
TW200510317A (en) Caspase inhibitors and uses thereof
MY142109A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY142423A (en) Substituted aminoacetyl pyrrolidine compounds which are dipeptidyl peptidase iv inhibitors, and pharmaceutical compositions containing them
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
DK1539700T3 (da) 8-hydroxyquinolin-derivater
SE0400284D0 (sv) Novel compounds
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
IL156873A0 (en) Pharmaceutically active piperidine derivatives
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
IL148313A0 (en) N-heterocyclic derivatives as nos inhibitors
DE60324544D1 (de) Muskarin antagonisten
TW200640900A (en) 1-(2h)-isoquinolone derivative
WO2004022528A3 (en) Arylglycine derivatives and their use as glycine transport inhibitors
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AU2003300385A8 (en) Anticancer compounds
DE60114640D1 (en) Antithrombosemittel
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.

Legal Events

Date Code Title Description
FG Grant or registration